1, (1,25D 3 ) has a potential antiatherosclerotic effect through anti-inflammatory actions. We investigated how 1,25D 3 regulates tumor necrosis factor-a (TNF-a)-induced lectinlike oxidized low-density lipoprotein receptor-1 (LOX-1) expression in cultured human aortic smooth muscle cells. TNF-a activated Rac1/reactive oxygen species/spleen tyrosine kinase and transcriptional factors, activator protein-1, and nuclear factor kB, which led to LOX-1 expression. 1,25D 3 inhibited TNF-a-induced LOX-1 expression by inhibiting Rac1 activation and thereby its downstream signals. 1,25D 3 rapidly induced extracellular Ca 21 influx. Verapamil, an inhibitor of L-type calcium channels, inhibited 1,25D 3 -induced Ca 21 influx and counteracted the inhibitory effects of 1,25D 3 on Rac1 activation, whereas Bay K8644 [1,4-dihydro-2,6-dimethyl-5-nitro-4-[2-(trifluoromethyl)phenyl]-3-pyridinecarboxylic acid, methyl ester], an L-type calcium channel agonist, attenuated TNF-a-induced Rac1 activation, as 1,25D 3 did. 1,25D 3 induced the ectodomain shedding of TNF receptor 1 (TNFR1), which was abolished by verapamil and in Ca 21 -free media. Like 1,25D 3 , Bay K8644 induced the ectodomain shedding of TNFR1. Both 1,25D 3 and Bay K8644 caused the translocation of a disintegrin and metalloprotease (ADAM) 10 from the cytoplasm to the plasma membrane, which was dependent on extracellular Ca 21 influx. In contrast, depletion of ADAM10 by transfection of ADAM10-small interfering RNA prevented 1,25D 3 -or Bay K8644-induced ectodomain shedding of TNFR1 and abolished the suppressive effect of 1,25D 3 on TNF-a-induced Rac1 activation. Taken together, these findings suggest that 1,25D 3 induces extracellular Ca 21 influx via L-type calcium channel, triggering ADAM10-mediated ectodomain shedding of TNFR1, and it thereby decreases responsiveness to TNF-a. By shedding TNFR1 from the cell surface, 1,25D 3 may regulate inflammation and atherogenesis, whereas this effect could be attenuated by calcium channel blockers.